Since Zaldivar's review of phakic intraocular lenses in these pages in 2000 [1••], further reports of experience with this technology have emerged. Their relative advantages and disadvantages over competing technologies are becoming clearer. Clinical trials, including Food & Drug Administration (FDA) trials, have shown predictability, stability, and efficacy. Safety of these implants over the long term remains a concern, but in some situations, at least, phakic intraocular lenses are becoming the refractive correction of choice. This brief review looks at the most recent data to emerge regarding phakic intraocular lenses.
The Eye Institute, Chatswood, New South Wales, Australia.
Correspondence to Michael A, Lawless, The Eye Institute, 270 Victoria Avenue, Chatswood, New South Wales, 2067, Australia; email@example.com